Literature DB >> 29378714

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery.

Matthieu Grégoire1,2, Julia Brochard Libois3, Denis Waast4, Benjamin Gaborit3,5, Marc Dauty6, Guillaume Deslandes7, Eric Dailly7,8, Sophie Touchais4, David Boutoille3,5, Nicolas Grégoire9, William Couet9.   

Abstract

An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC0-24) was 28.3 mg/liter · h. The AUC0-24/MIC ratio for unbound concentrations and for sensitive Staphylococcus and Streptococcus strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  bariatric surgery; obesity; pharmacokinetics; tedizolid

Mesh：

Substances：

Year:  2018        PMID： 29378714      PMCID： PMC5913932          DOI： 10.1128/AAC.02432-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.

Authors:  Yong Zhang; Meirong Huo; Jianping Zhou; Shaofei Xie
Journal:  Comput Methods Programs Biomed       Date:  2010-02-21       Impact factor: 5.428

2.  Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments.

Authors:  L Khatchatourian; A Le Bourgeois; N Asseray; C Biron; M Lefebvre; D Navas; M Grégoire; B Gaborit; F Raffi; D Boutoille
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 3.  RYGB and Drug Disposition: How to Do Better? Analysis of Pharmacokinetic Studies and Recommendations for Clinical Practice.

Authors:  Lorry Hachon; Xavier Declèves; Pauline Faucher; Claire Carette; Célia Lloret-Linares
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

4.  Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.

Authors:  Shawn Flanagan; Sonia L Minassian; Julie A Passarell; Jill Fiedler-Kelly; Philippe Prokocimer
Journal:  J Clin Pharmacol       Date:  2017-05-16       Impact factor: 3.126

5.  Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

Authors:  Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

6.  Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects?

Authors:  Rhonda Hamilton; Xia C Thai; Darius Ameri; Manjunath P Pai
Journal:  J Antimicrob Chemother       Date:  2012-11-15       Impact factor: 5.790

7.  Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

Authors:  S Flanagan; S L Minassian; D Morris; R Ponnuraj; T C Marbury; H W Alcorn; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

8.  Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.

Authors:  Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

9.  Simultaneous determination of tedizolid and linezolid in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study.

Authors:  Hua-chen Yu; Chen-wei Pan; Qi-peng Xie; Yi Zheng; Yue-zheng Hu; Yi-mu Lin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-01-02       Impact factor: 3.205

Review 10.  Review article: The nutritional and pharmacological consequences of obesity surgery.

Authors:  J Stein; C Stier; H Raab; R Weiner
Journal:  Aliment Pharmacol Ther       Date:  2014-07-30       Impact factor: 8.171
View more
  1 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Tedizolid.

Authors:  Khalid Iqbal; Aliki Milioudi; Sebastian Georg Wicha
Journal:  Clin Pharmacokinet       Date:  2022-02-07       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.